公开(公告)号：US12090186B2

公开(公告)日：2024-09-17

申请号：US17222768

申请日：2021-04-05

申请人： Moringo Organics Inc.

发明人： Karen Vieira ,  John Britto

IPC分类号： A61K36/00 ,  A61K9/00 ,  A61K9/48 ,  A61K31/4525 ,  A61K35/04 ,  A61K35/74 ,  A61K35/748 ,  A61K36/185 ,  A61K36/31 ,  A61K36/47 ,  A61K36/48 ,  A61K36/53 ,  A61K36/61 ,  A61K36/67 ,  A61K36/9066 ,  A61P3/06 ,  A61P3/10 ,  A61P39/06

CPC分类号： A61K36/31 ,  A61K9/0053 ,  A61K9/48 ,  A61K31/4525 ,  A61K35/04 ,  A61K35/74 ,  A61K35/748 ,  A61K36/185 ,  A61K36/47 ,  A61K36/48 ,  A61K36/53 ,  A61K36/61 ,  A61K36/67 ,  A61K36/9066 ,  A61P3/06 ,  A61P3/10 ,  A61P39/06 ,  A61K2300/00 ,  A61K2300/00 ,  A61K36/185 ,  A61K2300/00 ,  A61K36/47 ,  A61K2300/00 ,  A61K36/48 ,  A61K2300/00 ,  A61K36/53 ,  A61K2300/00 ,  A61K36/67 ,  A61K2300/00 ,  A61K36/9066 ,  A61K2300/00 ,  A61K35/74

摘要： The main objective of the present invention is to develop an herbal formulation with high polyphenol concentrations. A therapeutic effect of ingredients in herbal composition with Antioxidants, Anti-inflammatories, Anti Viral & Anti Microbial properties to reduce Oxidative Stress, Inflammation, Viral and Microbial Infections. The herbal composition promotes management of diabetes, regulation of cholesterol, also immune system processes that helps to fight against viral and bacterial infections, colds, or the flu, skin ailments such as Psoriasis & eczema. Herbal Composition comprises synergistic combination of Moringa oleifera Leaf Powder, Spirulina & Aqueous extracts of Oregano vulgare Leaf Extract, Shilajit extract, Rosemary Leaf extract, Pomegranate Fruit Preel extract, Amla fruit extract, Fenugreek Seed Extract, Curcumin Extract, Piperine extract. Therefore, the chosen herbal blend provides the body with all of the vitamins, minerals, and nutrients it needs to continuously boost health.

公开(公告)号：US11712433B2

公开(公告)日：2023-08-01

申请号：US16826131

申请日：2020-03-20

申请人： Sumitomo Pharma Oncology, Inc.

发明人： Steven L. Warner ,  David J. Bearss ,  Jason Marc Foulks

IPC分类号： A61K31/4155 ,  A61K35/04 ,  C07K16/28 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K31/4155 ,  A61K35/04 ,  A61P35/00 ,  A61P35/02 ,  C07K16/2818 ,  C07K16/2827 ,  A61K45/06

摘要： A compound of Structure (I):




or a pharmaceutically acceptable salt thereof, alone or in combination with a second therapeutic agent, as well as methods of treating a PKM2-mediated disease or disorder using the same are provided herein.

公开(公告)号：US20230218642A1

公开(公告)日：2023-07-13

申请号：US18119251

申请日：2023-03-08

申请人： Azura Ophthalmics Ltd.

发明人： Yair ALSTER ,  Omer RAFAELI ,  Kirsten Angela MACFARLANE ,  Cary REICH ,  Shimon AMSELEM ,  Doron FRIEDMAN

IPC分类号： A61K31/60 ,  A61K9/06 ,  A61K31/19 ,  A61K35/04 ,  A61K33/04 ,  A61K8/22 ,  A61K31/327 ,  A61K31/17 ,  A61K31/555 ,  A61K9/00 ,  A61K8/23 ,  A61K31/122 ,  A61K31/4015

CPC分类号： A61K31/60 ,  A61K9/06 ,  A61K31/19 ,  A61K35/04 ,  A61K33/04 ,  A61K8/22 ,  A61K31/327 ,  A61K31/17 ,  A61K31/555 ,  A61K9/0048 ,  A61K8/23 ,  A61K31/122 ,  A61K31/4015 ,  A61K9/0014

摘要： Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

公开(公告)号：US20190240502A1

公开(公告)日：2019-08-08

申请号：US16264444

申请日：2019-01-31

申请人： Luma Therapeutics, Inc.

发明人： Evan R. ANDERSON ,  Adam MARTOS ,  Christopher Steven PELL

IPC分类号： A61N5/06 ,  A61K35/04 ,  A61K9/06

CPC分类号： A61N5/0616 ,  A61K9/06 ,  A61K35/04 ,  A61N5/06 ,  A61N2005/0627 ,  A61N2005/0645 ,  A61N2005/0652 ,  A61N2005/0661 ,  A61N2005/0667

摘要： Compositions, methods and apparatuses for phototherapy to treat skin disorders. In particular, described herein are methods, compositions, phototherapy dressings for use with phototherapy UV light applicators (sources) and phototherapy UV light applicators to treat skin disorders such as psoriasis.

公开(公告)号：US20190209634A1

公开(公告)日：2019-07-11

申请号：US15563617

申请日：2017-06-01

申请人： MORINGO ORGANICS INC.

发明人： Karen Vieira

IPC分类号： A61K36/31 ,  A61K36/53 ,  A61K35/04 ,  A61K35/748 ,  A61K36/185 ,  A61K31/4525 ,  A61K36/67 ,  A61K9/00 ,  A61K9/48 ,  A61K36/61 ,  A61K36/48 ,  A61K36/9066 ,  A61P39/06 ,  A61P3/10 ,  A61P3/06

CPC分类号： A61K36/31 ,  A61K9/0053 ,  A61K9/48 ,  A61K31/4525 ,  A61K35/04 ,  A61K35/74 ,  A61K35/748 ,  A61K36/185 ,  A61K36/47 ,  A61K36/48 ,  A61K36/53 ,  A61K36/61 ,  A61K36/67 ,  A61K36/9066 ,  A61K2300/00 ,  A61P3/06 ,  A61P3/10 ,  A61P39/06

摘要： The main objective of the present invention is to develop an herbal formulation with high polyphenol concentrations. A therapeutic effect of ingredients in herbal composition with Antioxidants, Anti-inflammatories, Anti Viral & Anti Microbial properties to reduce Oxidative Stress, Inflammation, Viral and Microbial Infections. The herbal composition promotes management of diabetes, regulation of cholesterol, also immune system processes that helps to fight against viral and bacterial infections, colds, or the flu, skin ailments such as Psoriasis & eczema. Herbal Composition comprises synergistic combination of Moringa Oleifera Leaf Powder, Spirulina & Aqueous extracts of Oregano Vulgare Leaf Extract, Shilajit extract, Rosemary Leaf extract, Pomegranate Fruit Preel extract, Amla fruit extract, Fenugreek Seed Extract, Curcumin Extract, Piperine extract. Therefore, the chosen herbal blend provides the body with all of the vitamins, minerals, and nutrients it needs to continuously boost health.

公开(公告)号：US20180369321A1

公开(公告)日：2018-12-27

申请号：US16020457

申请日：2018-06-27

申请人： The Regents of the University of Michigan

发明人： Tom K. Kerppola ,  Veronica E. Burns

IPC分类号： A61K38/12 ,  A61P5/46 ,  A61P5/42 ,  A61P35/00 ,  A61K45/06

CPC分类号： A61K38/12 ,  A61K31/17 ,  A61K31/18 ,  A61K31/277 ,  A61K31/352 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/5685 ,  A61K31/64 ,  A61K35/04 ,  A61K38/13 ,  A61K45/06 ,  A61K2300/00 ,  A61P5/42 ,  A61P5/46 ,  A61P35/00

摘要： Provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production. In particular, provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production through administration of at least one of the following agents: 1) an agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1; 2) an agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity; and 3) an agent capable of inhibiting mitochondrial activity.

公开(公告)号：US20170172857A1

公开(公告)日：2017-06-22

申请号：US15368231

申请日：2016-12-02

申请人： Foamix Pharmaceuticals Ltd.

发明人： Dov TAMARKIN ,  Doron FRIEDMAN ,  Meir EINI ,  Alex BESONOV

IPC分类号： A61K8/04 ,  A61K8/37 ,  A61K8/49 ,  A61K8/81 ,  A61K8/96 ,  A61K9/12 ,  A61K35/04 ,  A61K47/06 ,  A61K47/14 ,  A61K47/22 ,  A61Q19/00 ,  A61K47/32 ,  A61K47/38 ,  A61K8/73 ,  A61K8/31

CPC分类号： A61K8/046 ,  A01N25/16 ,  A61K8/062 ,  A61K8/31 ,  A61K8/37 ,  A61K8/375 ,  A61K8/4973 ,  A61K8/731 ,  A61K8/8176 ,  A61K8/965 ,  A61K9/0014 ,  A61K9/107 ,  A61K9/122 ,  A61K35/04 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22 ,  A61K47/32 ,  A61K47/38 ,  A61Q19/00 ,  A61Q19/02 ,  A61Q19/08

摘要： The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least one surface-active agent; (3) water; and (4) at least one liquefied or compressed gas propellant at a concentration of 3% to 25% by weight of the total composition.The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering the above-mentioned compositions to an afflicted target site.

公开(公告)号：US20160220609A1

公开(公告)日：2016-08-04

申请号：US14917873

申请日：2014-09-09

申请人： NATREON, INC.

发明人： Chandan K. Sen

IPC分类号： A61K35/04 ,  A61K35/66

CPC分类号： A61K35/04 ,  A61K31/37 ,  A61K35/66 ,  A61K36/09 ,  A61K2300/00

摘要： A method of using Purified Shilajit to promote steroidogenic activity in a mammal is provided.

摘要翻译： 提供了使用纯化Shilajit促进哺乳动物中的类固醇生成活性的方法。

公开(公告)号：US20140356466A1

公开(公告)日：2014-12-04

申请号：US14293754

申请日：2014-06-02

申请人： Natreon, Inc.

发明人： Ramesh C. Gupta ,  Aundrea Fleck ,  Sanyasi R. Kalidindi

IPC分类号： A61K36/185

CPC分类号： A61K36/47 ,  A61K33/00 ,  A61K35/04 ,  A61K2300/00

摘要： Chromium-three cation in combination with Phyllanthus emblica extract and Shilajit is useful in treating symptoms associated with osteoarthritis including reduction of inflammation and pain in a mammal, particularly a human or an animal. The combination shows significant reduction in overall pain levels and other pain measures in a canine model, and in human studies. Thus the composition is an anti-arthritic formulation that decreases pain and inflammation.

摘要翻译： 与三叶草提取物和Shilajit组合的三价铬阳离子可用于治疗与骨关节炎相关的症状，包括哺乳动物，特别是人或动物的炎症和疼痛的减轻。 该组合显示犬模型和人类研究中的总体疼痛水平和其他疼痛措施的显着降低。 因此，该组合物是减轻疼痛和炎症的抗关节炎制剂。

公开(公告)号：US20140248270A1

公开(公告)日：2014-09-04

申请号：US14276470

申请日：2014-05-13

申请人： Ruey J. YU ,  Eugene J. VAN SCOTT

发明人： Ruey J. YU ,  Eugene J. VAN SCOTT

IPC分类号： A61K35/04 ,  A61K9/00 ,  A61K47/14 ,  A61K45/06

CPC分类号： A61K35/04 ,  A61K9/0014 ,  A61K36/00 ,  A61K45/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/32 ,  A61K47/38 ,  A61K47/44 ,  A61K2300/00

摘要： A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder, the composition including a wax and a therapeutically effective amount of tar for topical treatment of the tar-responsive dermatological disorder, the composition being in liquid form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal.

摘要翻译： 治疗焦油反应性皮肤病的方法包括将无水焦油组合物局部施用于与病症有关的哺乳动物，优选人的皮肤，所述组合物包括蜡和治疗有效量的用于局部治疗的焦油 焦油反应性皮肤病，当将组合物施用于哺乳动物的皮肤时，当选自室温和哺乳动物皮肤温度的温度时，组合物为液体形式。